Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam effective dose for laryngeal mask insertion in children with sufentanil
ChiCTR2400087333Phase 4Recruiting
- Sponsor
- Shanghai Children's Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and sufentanil (3 arms), sponsored by Shanghai Children's Hospital. Primary endpoints: Positive response to laryngeal mask implantation, ED50 of remimazolam for inhibiting laryngeal mask implantation response and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
remimazolamsufentanil
Beyond the preview
Go deeper on ChiCTR2400087333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087333.